"10.1371_journal.pone.0102832","plos one","2014-07-31T00:00:00Z","Marei Sammar; Shahar Nisamblatt; Ron Gonen; Berthold Huppertz; Sveinbjorn Gizurarson; George Osol; Hamutal Meiri","Prof. Ephraim Katzir Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel; Department of Obstetrics and Gynecology, Bnai Zion Medical Center, and Technion-Israel Institute of Technology, Haifa, Israel; Institute of Cell Biology, Histology and Embryology/Biobank Graz, Medical University of Graz, Graz, Austria; Faculty of Pharmaceutical Sciences, School of Health Science, University of Iceland, Reykjavik, Iceland; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Vermont College of Medicine, Burlington, Vermont, United States of America; Telemarpe Ltd, Tel Aviv, and Hy-Laboratories, Rehovot, Israel","Conceived and designed the experiments: MS SG GO HM. Analyzed the data: MS SN BH SG GO HM. Contributed reagents/materials/analysis tools: MS SN SG HM. Contributed to the writing of the manuscript: MS SN BH SG GO HM. Contributed clinical material and databases: RG. Contributed methodology of analysis: BH. Contributed experimental models: GO.","Please be advised that the only author who is an employee of TeleMarpe is Dr. Hamutal Meiri. The financial disclosure of Dr. Meiri with regards to the patent for the biological effects of PP13 as a potential drug to prevent/cure from preeclampsia has been stated and the specific referral to the issued patent has been added. Dr. Meiri’s employment, consultancy, and other duties to TeleMarpe in terms of patents, product development or marketed products have been thereby fully disclosed. All authors including Dr. Hamutal Meiri and Dr. Sveinbjorn Gizurarson are fully committed to adherence to all PLOS ONE policies on sharing data and materials, as detailed online in the journal guide for authors as detailed in http://www.PLOSone.org/static/editorial.action# competing. Dr. Sveinbjorn Gizurarson and Dr. Hamutal Meiri are the inventors of a USA patent 2014/0031274A issued January 30, 2014 with the title of: “Biological activities of placental protein 13” with patent rights assigned to the University of Iceland, Hananja ehf and TeleMarpe Ltd. This follows the PCT # IS2011/050014 of the same title. The authors hereby confirm on behalf of all authors including Dr. Gizurarson and Dr. Meiri that this patent or any of the old patents for the Pp13 technology do not alter their adherence to all PLOS ONE policies on sharing data and materials, as detailed online in the journal guide for authors http://www.PLOSone.org/static/editorial.action#competing.","2014","07","Marei Sammar","MS",7,TRUE,4,NA,6,NA,TRUE,TRUE,FALSE,0,NA,FALSE
